



Drug Quantity Management – Per Rx Oncology – Iressa® (gefitinib tablets)

Table of Contents

National Formulary Medical Necessity	1
Conditions Not Covered.....	2
Background.....	2
References	2
Revision History.....	2

Product Identifier(s)

Effective 1/1/23 to 3/21/23: 109690

Effective 3/22/23: 52160

INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer's particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer's benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

National Formulary Medical Necessity

This Drug Quantity Management program has been developed to promote the safe, effective, and economic use of Iressa. If the Drug Quantity Management rule is not met for the requested medication at the point of service, coverage will be determined by the Criteria below. All approvals are provided for 1 year in duration.

Drug Quantity Limit

Product	Strength and Form	Retail Maximum Quantity per Rx
Iressa® (gefitinib tablets)	250 mg tablets	30 tablets

Criteria

Cigna covers quantities as medically necessary when the following criteria are met:

1. If the individual is taking a strong cytochrome P450 (CYP)3A4 inducer, approve 60 tablets per dispensing at retail or 180 tablets per dispensing at home delivery. Note: CYP3A4 inducers include, but are not limited to, rifampicin, carbamazepine, phenobarbital, phenytoin, rifabutin, rifapentine, and St. John's Wort.

Conditions Not Covered

Any other exception is considered not medically necessary.

Background

Overview

Indication

Iressa, a tyrosine kinase inhibitor, is indicated for the first-line treatment of patients with metastatic **non-small cell lung cancer** (NSCLC) whose tumors have epidermal growth factor receptor (*EGFR*) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.¹ The safety and efficacy of Iressa have not been established in patients with metastatic NSCLC whose tumors have *EGFR* mutations other than exon 19 deletions or exon 21 (L858R) substitution mutations.

Dosing

The recommended dose of Iressa for treatment of NSCLC is 250 mg once daily (QD).¹ The dose may need to be withheld due to adverse events, hepatic enzyme elevations or drug interactions with cytochrome P450 (CYP)3A4 inhibitors. CYP3A4 inducers may decrease gefitinib plasma concentrations. Therefore, the dose of Iressa should be increased to 500 mg QD, as tolerated, in patients taking strong CYP3A4 inducers (e.g., rifampicin, phenytoin, or tricyclic antidepressant). The dose should be decreased to 250 mg QD 7 days after discontinuation of the CYP3A4 inducer.

Availability

Iressa is available as 250 mg tablets in bottles containing 30 tablets each.¹

References

1. Iressa® tablets [prescribing information]. Wilmington, DE: AstraZeneca; May 2021.

Revision History

Type of Revision	Summary of Changes	Approval Date
Annual Revision	No change to criteria. Policy was updated to reflect the existing quantity limits when a product is obtained via home delivery.	11/09/2022

"Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc. and HMO or service company subsidiaries of Cigna Health Corporation. The Cigna name, logo, and other Cigna marks are owned by Cigna Intellectual Property, Inc. © 2023 Cigna.